Apr 7, 2026 8:00am EDT Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Apr 3, 2026 2:01pm EDT Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)